Nicola Guess
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nicola Guess has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Nick Oliver
Department of Metabolism, Digestion and Reproduction, Imperial College London
3 shared publicationsPaul Aveyard
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
3 shared publicationsAbeer El Samad
Dasman Diabetes Institute Kuwait City Kuwait
2 shared publicationsBrandon Whitcher
Department of Life Sciences University of Westminster London UK
2 shared publicationsCaroline Mitchell
Academic Unit of Primary Medical Care, Faculty of Medicine, University of Sheffield, Sheffield, UK
2 shared publicationsCarolyn Newbert
Expert by Experience, Oxford, UK
2 shared publications
Latest Publications
- 6 October 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (10) , 1941-1942
Metabolic advantages of a high-protein, low-carbohydrate diet in in patients with metabolically unhealthy obesity
- 6 October 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (10) , 1941-1942
Metabolic advantages of a high-protein, low-carbohydrate diet in in patients with metabolically unhealthy obesity
- 9 March 2026
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 22 (7) , 433-443
Hyperinsulinaemia as a cause of obesity and cardiometabolic diseases
This narrative Review explores the role of hyperinsulinaemia as a potential independent contributor to obesity and cardiometabolic diseases. We argue that scientific discussions about the role of hyperinsulinaemia as a causal factor in these conditions have not sufficiently distinguished between postprandial insulin excursions and chronically elevated basal levels of insulin. We summarize findings from observational and experimental human trials, as well as preclinical models, and outline how reasonable evidence suggests that chronic (basal) exposure to elevated levels of insulin, rather than normal postprandial insulin excursions in isolation, might have a role in promoting or exacerbating the development of adiposity. We discuss the putative contributors to hyperinsulinaemia, including genetic predisposition, early-life influences, diet, environmental pollutants and physical inactivity, highlighting causality knowledge gaps relevant to the prevention of obesity and cardiometabolic diseases.
- 9 March 2026
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 22 (7) , 433-443
Hyperinsulinaemia as a cause of obesity and cardiometabolic diseases
This narrative Review explores the role of hyperinsulinaemia as a potential independent contributor to obesity and cardiometabolic diseases. We argue that scientific discussions about the role of hyperinsulinaemia as a causal factor in these conditions have not sufficiently distinguished between postprandial insulin excursions and chronically elevated basal levels of insulin. We summarize findings from observational and experimental human trials, as well as preclinical models, and outline how reasonable evidence suggests that chronic (basal) exposure to elevated levels of insulin, rather than normal postprandial insulin excursions in isolation, might have a role in promoting or exacerbating the development of adiposity. We discuss the putative contributors to hyperinsulinaemia, including genetic predisposition, early-life influences, diet, environmental pollutants and physical inactivity, highlighting causality knowledge gaps relevant to the prevention of obesity and cardiometabolic diseases.
- 16 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (4) , 1176-1177
Precision nutrition must consider cost-effectiveness to deliver benefits to patients
- 16 February 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (4) , 1176-1177
Precision nutrition must consider cost-effectiveness to deliver benefits to patients
- Open Access
- 1 October 2025
- Published by Springer Nature in Research Involvement and Engagement
- Vol. 11 (1) , 1-10
Developing powerful PPIE partnerships in the design of an inclusive weight management service: a case study from the NewDAWN programme
Weight loss programmes can help people achieve remission of type 2 diabetes (T2D). People from underserved communities are less likely to participate in—and may experience poorer outcomes from—weight loss programmes than people from healthier populations already better served by healthcare systems. Unless health services including weight management programmes are based on the needs of the people most in need of them, health inequalities may get worse. Here we describe how PPIE—with a specific focus on reaching the most underserved communities—has shaped a new weight management service for T2D remission and impacted the study design, stimulating new ideas to further engagement and enhance outcomes from remission programmes more broadly. We assess our approach against the UK Standards for Public Involvement in Research and the Diabetes UK Addressing Health Inequalities in Diabetes Through Research guidance, and reflect upon achievements and areas for further development.
- 1 October 2025
- Published by Springer Nature in Research Involvement and Engagement
- Vol. 11 (1) , 1-10
Open AccessDeveloping powerful PPIE partnerships in the design of an inclusive weight management service: a case study from the NewDAWN programme
Weight loss programmes can help people achieve remission of type 2 diabetes (T2D). People from underserved communities are less likely to participate in—and may experience poorer outcomes from—weight loss programmes than people from healthier populations already better served by healthcare systems. Unless health services including weight management programmes are based on the needs of the people most in need of them, health inequalities may get worse. Here we describe how PPIE—with a specific focus on reaching the most underserved communities—has shaped a new weight management service for T2D remission and impacted the study design, stimulating new ideas to further engagement and enhance outcomes from remission programmes more broadly. We assess our approach against the UK Standards for Public Involvement in Research and the Diabetes UK Addressing Health Inequalities in Diabetes Through Research guidance, and reflect upon achievements and areas for further development.
- Open Access
- 25 August 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 157, 108050
Testing a New Diabetes Adaptive Weight management Network (NewDAWN): A protocol for a randomised controlled trial
- 25 August 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 157, 108050
Open AccessTesting a New Diabetes Adaptive Weight management Network (NewDAWN): A protocol for a randomised controlled trial
- Open Access
A randomised crossover trial of high- versus low-protein diets on glycaemia in people with normal glucose tolerance (NGT) and type 2 diabetes (T2D)
Objective To determine whether a low-carbohydrate, high-protein diet lowers glucose compared to a low-carbohydrate, normal-protein diet. Research Design and Methods A total of 11 participants with type 2 diabetes (T2D) and 9 with normal glucose tolerance (NGT) were prescribed diets high (30%kcal) and low (15%kcal) in protein with carbohydrate kept constant (20%kcal), in randomised order (high-protein > low-protein > high-protein or low-protein > high-protein > low-protein sequence) following an initial run-in period of 1-2 days where participants followed their habitual diet (protein 15kcal; carbohydrate ∼45%kcal). Glucose was measured using blinded continuous glucose monitoring Results In people with T2D, 24-hour and post-prandial AUC □ □ □ were significantly lower (- 1.0mmol/L, 95%CI: -1.2 to -0.8, and (381.4 mmol/L*180, 95%CI: -443.5 to -319.3) and time in range (TIR) significantly higher (13.9%, 95%CI: 10.0 to 17.8) for the high-protein condition, compared to the low-protein condition. For people with NGT only post-prandial sensor glucose was lower on the high-protein compared to low-protein condition. Conclusion A high-protein, reduced-carbohydrate diet could be useful as a standalone or an adjunct to weight loss to help achieve optimum glucose concentrations for people with T2D. Trial registration and protocol: ISRCTN26058700.
Open AccessA randomised crossover trial of high- versus low-protein diets on glycaemia in people with normal glucose tolerance (NGT) and type 2 diabetes (T2D)
Objective To determine whether a low-carbohydrate, high-protein diet lowers glucose compared to a low-carbohydrate, normal-protein diet. Research Design and Methods A total of 11 participants with type 2 diabetes (T2D) and 9 with normal glucose tolerance (NGT) were prescribed diets high (30%kcal) and low (15%kcal) in protein with carbohydrate kept constant (20%kcal), in randomised order (high-protein > low-protein > high-protein or low-protein > high-protein > low-protein sequence) following an initial run-in period of 1-2 days where participants followed their habitual diet (protein 15kcal; carbohydrate ∼45%kcal). Glucose was measured using blinded continuous glucose monitoring Results In people with T2D, 24-hour and post-prandial AUC □ □ □ were significantly lower (- 1.0mmol/L, 95%CI: -1.2 to -0.8, and (381.4 mmol/L*180, 95%CI: -443.5 to -319.3) and time in range (TIR) significantly higher (13.9%, 95%CI: 10.0 to 17.8) for the high-protein condition, compared to the low-protein condition. For people with NGT only post-prandial sensor glucose was lower on the high-protein compared to low-protein condition. Conclusion A high-protein, reduced-carbohydrate diet could be useful as a standalone or an adjunct to weight loss to help achieve optimum glucose concentrations for people with T2D. Trial registration and protocol: ISRCTN26058700.
- Open Access
- 15 April 2024
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 174, 230-236
Evaluating the efficacy and mechanisms of a ketogenic diet as adjunctive treatment for people with treatment-resistant depression: A protocol for a randomised controlled trial
- 15 April 2024
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 174, 230-236
Open AccessEvaluating the efficacy and mechanisms of a ketogenic diet as adjunctive treatment for people with treatment-resistant depression: A protocol for a randomised controlled trial
- Open Access
- 19 March 2024
- Published by Springer Nature
A remotely delivered behavioural support programme can help people with type 2 diabetes follow a low-carbohydrate, low-energy diet
- 19 March 2024
- Published by Springer Nature
Open AccessA remotely delivered behavioural support programme can help people with type 2 diabetes follow a low-carbohydrate, low-energy diet
- 26 January 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (8) , 1420-1422
Big data and personalized nutrition: the key evidence gaps
- 26 January 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (8) , 1420-1422
Big data and personalized nutrition: the key evidence gaps
- 15 November 2023
- Published by Springer Nature in Amino Acids
- Vol. 55 (12) , 1857-1866
Amino acid-stimulated insulin secretion: a path forward in type 2 diabetes
Qualitative and quantitatively appropriate insulin secretion is essential for optimal control of blood glucose. Beta-cells of the pancreas produce and secrete insulin in response to glucose and non-glucose stimuli including amino acids. In this manuscript, we review the literature on amino acid-stimulated insulin secretion in oral and intravenous in vivo studies, in addition to the in vitro literature, and describe areas of consensus and gaps in understanding. We find promising evidence that the synergism of amino acid-stimulated insulin secretion could be exploited to develop novel therapeutics, but that a systematic approach to investigating these lines of evidence is lacking. We highlight evidence that supports the relative preservation of amino acid-stimulated insulin secretion compared to glucose-stimulated insulin secretion in type 2 diabetes, and make the case for the therapeutic potential of amino acids. Finally, we make recommendations for research and describe the potential clinical utility of nutrient-based treatments for type 2 diabetes including remission services.
- 15 November 2023
- Published by Springer Nature in Amino Acids
- Vol. 55 (12) , 1857-1866
Amino acid-stimulated insulin secretion: a path forward in type 2 diabetes
Qualitative and quantitatively appropriate insulin secretion is essential for optimal control of blood glucose. Beta-cells of the pancreas produce and secrete insulin in response to glucose and non-glucose stimuli including amino acids. In this manuscript, we review the literature on amino acid-stimulated insulin secretion in oral and intravenous in vivo studies, in addition to the in vitro literature, and describe areas of consensus and gaps in understanding. We find promising evidence that the synergism of amino acid-stimulated insulin secretion could be exploited to develop novel therapeutics, but that a systematic approach to investigating these lines of evidence is lacking. We highlight evidence that supports the relative preservation of amino acid-stimulated insulin secretion compared to glucose-stimulated insulin secretion in type 2 diabetes, and make the case for the therapeutic potential of amino acids. Finally, we make recommendations for research and describe the potential clinical utility of nutrient-based treatments for type 2 diabetes including remission services.